Introduction {#s1}
============

Type 2 diabetes (T2D) is a complex metabolic disease characterised by hyperglycemia, insulin resistance, impaired insulin secretion due to pancreatic β-cell defects and increased hepatic glucose production. Despite much investigation, the causes underlying the development and progression of T2D have not been fully elucidated, accumulated evidence suggests that multiple genetic and environmental factors, as well as the interplay between these factors, determine the phenotype. Although the genetic contribution to T2D is well recognized, the current set of 56 established susceptibility loci, identified primarily through large-scale genome-wide association studies (GWAS), captures at best 10% of familial aggregation of the disease [@pone.0055727-Zeggini1]--[@pone.0055727-Voight1]. This has maintained interest in other biochemical and genetic factors that might contribute to the underlying pathophysiology of the disease.

Glucokinase (*GCK*) is the key glucose phosphorylation enzyme responsible for the first rate-limiting step in the glycolysis pathway and regulates glucose-stimulated insulin secretion from pancreatic β-cells and glucose metabolism in the liver [@pone.0055727-Matschinsky1]. Inactivating *GCK* mutations lead to maturity-onset diabetes of the young and neonatal diabetes [@pone.0055727-Froguel1]--[@pone.0055727-Njlstad1], whereas activating *GCK* mutations cause persistent hyperinsulinaemic hypoglycaemia [@pone.0055727-Christesen1]--[@pone.0055727-Gloyn2]. Moreover, a common variant (−30G\>A, rs1799884) in the pancreatic beta cell-specific promoter of *GCK* has been shown to be associated with increased risk of type 2 diabetes, hyperglycaemia and impaired beta cell function [@pone.0055727-Vaxillaire1]--[@pone.0055727-Yamada1]. Furthermore, GCK −30 A\>G has been conclusively associated with fasting glucose in European populations [@pone.0055727-Weedon1].

To date, many case--control studies have been carried out to investigate the role of the *GCK* −30G\>A polymorphism in the development of T2D among various populations. Genetic association studies can be problematic to reproduce due to insufficient power, multiple hypothesis testing, population stratification, source of controls, publication bias, and phenotypic heterogeneity. In addition, with the increased studies in recent years among Asian, and other populations, there is a need to reconcile these data. We therefore conducted a comprehensive meta-analysis to quantify the overall risk of *GCK* −30G\>A polymorphism on developing T2D.

Materials and Methods {#s2}
=====================

Literature Search Strategy {#s2a}
--------------------------

Genetic association studies published before the end of Sep. 2012 on T2D and polymorphisms within GCK gene were identified through a search of PubMed, ISI Web of Science, EMBASE and CNKI (Chinese National Knowledge Infrastructure) without language restrictions. Search term combinations were keywords relating to the glucokinase gene (e.g., "glucokinase", "GCK", and "MODY 2") in combination with words related to T2D (e.g., "type 2 diabetes mellitus", "T2DM", "type 2 diabetes", "T2D", "non-insulin-dependent diabetes mellitus" and "NIDDM") and polymorphism or variation. The search was supplemented by reviews of reference lists for all relevant studies and review articles. The major inclusion criteria were (a) original papers containing independent data, (b) case--control or cohort studies and (c) genotype distribution information or odds ratio (OR) with its 95% confidence interval (CI) and P-value. The major reasons for exclusion of studies were (a) overlapping data and (b) case-only studies, family-based studies and review articles.

Data Extraction {#s2b}
---------------

Data extraction was performed independently by two reviewers, and differences were resolved by further discussion among all authors. For each included study, the following information was extracted from each report according to a fixed protocol: first author's surname, publication year, definition and numbers of cases and controls, diagnostic criterion, frequency of genotypes, source of controls, age, gender, body mass index (BMI), Hardy--Weinberg equilibrium status, ethnicity and genotyping method. Not all researchers use the same SNP, we report herein 2 common SNPs (rs1799884 and rs4607517), as these SNPs are in complete disequilibrium (r^2^ = 1) [@pone.0055727-Prokopenko1].

Statistical Methods {#s2c}
-------------------

The strength of association between −30G\>A polymorphism of *GCK* and T2D risk was assessed by odds ratio (OR) with the corresponding 95% confidence interval (CI). We first used the chi square test to check if there was significant deviation from Hardy--Weinberg equilibrium among the control subjects in each study. The meta-analysis examined the association between each polymorphism and the risk of T2D for the: (i) allele contrast, (ii) dominant, and (iii) recessive model. For continuity variable, weighted mean difference (WMD) was used to pool results from studies.

Heterogeneity across individual studies was calculated using the Cochran chi-square Q test followed by subsidiary analysis or by random-effects regression models with restricted maximum likelihood estimation [@pone.0055727-Cochran1]--[@pone.0055727-Thompson1]. Random-effects and fixed-effect summary measures were calculated as inverse variance-weighted average of the log OR. The results of random-effects summary were reported in the text because it takes into account the variation between studies. In addition, we investigated potential sources of identified heterogeneity among studies by stratification according to the number of T2D cases (≥1000 and \<1000), ethnic group and diagnostic criteria (WHO, ADA or other criterion). Ethnic group was defined as Asians, Caucasians (i.e. people of European origin) and others (e.g. Tunisian and African--American). The Z test was used to determine the significance of the pooled OR. Gender distribution in cases and controls, genotyping method and mean age of cases and controls were analysed as covariates in meta-regression. The transcript expression level trends by genotypes were evaluated by using general linear model.

We assessed publication bias by using an ancillary procedure attributed to Egger et al. [@pone.0055727-Egger1], which uses a linear regression approach to measure funnel plot asymmetry on the natural logarithm of the OR. Sensitivity analysis was performed by removing each individual study in turn from the total and re-analysing the remainder. This procedure was used to ensure that no individual study was entirely responsible for the combined results. All statistical analyses were carried out with the Stata software version 10.0 (Stata Corporation, College Station, TX, USA). The type I error rate was set at 0.05. All the P-values were for two-sided analysis.

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

Study selection process was shown in [Figure S1](#pone.0055727.s001){ref-type="supplementary-material"}. In all, we included 36 data points from 24 studies in this meta-analysis, with a total of 88, 229 cases and 210, 239 controls [@pone.0055727-Vaxillaire1]--[@pone.0055727-Rose1], [@pone.0055727-Yamada1], [@pone.0055727-Prokopenko1], [@pone.0055727-Cauchi1]--[@pone.0055727-Chiu1]. The distribution of genotypes in the controls was consistent with Hardy--Weinberg equilibrium in all studies. Of the cases, 75% were Caucasians 21% were Asians and 4% were of other ethnic origins. The main study characteristics were summarized in [Table 1](#pone-0055727-t001){ref-type="table"}.
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###### Characteristics of the studies included in the meta-analysis.

![](pone.0055727.t001){#pone-0055727-t001-1}

  Reference                                 Year            Ethnicity                           Case                                       Control                         No. of case   No. of control             Genotyping method
  ---------------------------------------- ------ ------------------------------ ----------------------------------- ---------------------------------------------------- ------------- ---------------- ----------------------------------------
  Cauchi [@pone.0055727-Hu1]                2012               Arab                     T2D per WHO criteria                               Healthy                            2639            1997                        TaqMan
  Cho [@pone.0055727-Murad1]                2011              Asian                         T2D patients                          Non-diabetic participants                   6952           11865                       Genechip
  Kooner [@pone.0055727-Tam1]               2011              Asian                         T2D patients                          Non-diabetic participants                   5561           14458                       Genechip
  Hu [@pone.0055727-Dupuis1]                2010             Chinese                    T2D per WHO criteria                       Normal glucose tolerance                   3410            3412                      MassArray
  Murad [@pone.0055727-Ezzidi1]             2010             British                        T2D patients                          Non-diabetic participants                   1551            2993                        TaqMan
  Tam [@pone.0055727-Reiling1]              2010             Chinese                    T2D per WHO criteria                        Normal fasting glucose                    1320            1595                      MassArray
  Dupuis [@pone.0055727-Qi1]                2010   European, American, Austrian       T2D per WHO/ADA criteria                    Non-diabetic participants                   40655          87022        SNPstream, Genechip, TaqMan, MassArray
  Ezzidi [@pone.0055727-Ma1]                2009             Tunisian                   T2D per ADA criteria                      Normoglycemic participants                   865            505                         TaqMan
  Prokopenko [@pone.0055727-Prokopenko1]    2009             European             T2D per WHO criteria; T2Dpatients   Normal glucose tolerant; Non-diabetic participants      11785          49799                       Genechip
  Reiling [@pone.0055727-Cauchi2]           2009              Dutch                     T2D per WHO criteria                       Normal glucose tolerance                   2498            1912                        TaqMan
  Qi [@pone.0055727-Holmkvist1]             2009             Chinese                    T2D per WHO criteria                        Normal fasting glucose                     416            1877                      SNPstream
  Ma [@pone.0055727-Winckler1]              2009             Chinese                    T2D per WHO criteria                      Non-diabetic participants                    279            110                          RFLP
  Cauchi [@pone.0055727-Bonnycastle1]       2008              French                    T2D per ADA criteria                      Normoglycemic participants                  2637            4159                        TaqMan
  Vaxillaire [@pone.0055727-Vaxillaire1]    2008              French                    T2D per ADA criteria                      Normoglycemic participants                   292            2752                        TaqMan
  Holmkvist [@pone.0055727-Rissanen1]       2008             Swedish                    T2D per ADA criteria                      Non-diabetic participants                   1988           15019                        TaqMan
  Winckler [@pone.0055727-Lotfi1]           2007             British                    T2D per WHO criteria                      Non-diabetic participants                   2248            3561                      MassArray
  Bonnycastle [@pone.0055727-Shimokawa1]    2006             Finnish                    T2D per WHO criteria                       Normal glucose tolerance                    784            617                       MassArray
  Rose [@pone.0055727-Rose1]                2005               Dane                     T2D per WHO criteria                       Normal glucose tolerance                   1408            4773                      MassArray
  März [@pone.0055727-Mrz1]                 2004             Austrian                   T2D per ADA criteria                      Non-diabetic participants                    463            830                          RFLP
  Rissanen [@pone.0055727-Chiu1]            1998             Finnish                        T2D patients                           Normal glucose tolerance                    36             294                          SSCP
  Yamada [@pone.0055727-Yamada1]            1997             Japanese                   T2D per WHO criteria                       Normal glucose tolerance                    94             321                          RFLP
  Lotfi [@pone.0055727-Poulsen1]            1997             Swedish                    T2D per WHO criteria                               Healthy                             31             158                          SSCP
  Shimokawa [@pone.0055727-Coutinho1]       1994             Japanese                       T2D patients                          Non-diabetic participants                    240            111                          SSCP
  Chiu [@pone.0055727-Panzer1]              1994         American Blacks                T2D per NDDG criteria                     Non-diabetic participants                    77              99                          SSCP

Association of GCK −30G\>A Variant with T2D {#s3b}
-------------------------------------------

For T2D risk and the −30G\>A polymorphism of *GCK*, our meta-analysis gave an overall OR of 1.06 (95% CI: 1.03--1.09; *P*\<10^−4^; [Fig. 1](#pone-0055727-g001){ref-type="fig"}). Significantly increased T2D risks were also found under dominant (OR = 1.08; 95% CI: 1.01--1.19; *P* = 0.003) and recessive genetic models (OR = 1.12; 95% CI: 1.01--1.25; *P* = 0.008). This analysis is based on pooling of data from a number of different ethnic populations. When stratifying for ethnicity, an OR of 1.08 (95% CI: 1.04--1.12; *P*\<10^−4^), 1.01 (95% CI: 0.98--1.05; *P* = 0.53) and 1.13 (95% CI: 1.04--1.24; *P* = 0.006) resulted for the A allele, among Caucasian, Asian and other ethnic population, respectively. Similar results were also detected using dominant and recessive genetic models ([Table 2](#pone-0055727-t002){ref-type="table"}). When studies were stratified for sample size, significant risks were found among studies with small sample size in all genetic model (A allele: OR = 1.14, 95% CI: 1.04--1.25; dominant model: OR = 1.17, 95% CI: 1.06--1.28; recessive model: OR = 1.23, 95% CI: 1.05--1.43). Positive results still maintained for large sample size studies in all genetic models. Subsidiary analyses of diagnostic criterion yielded a per-allele OR for WHO criterion of 1.06 (95% CI: 1.01--1.11; *P* = 0.02), ADA criterion of 1.13 (95% CI: 0.99--1.28; *P* = 0.06) and for other criterion of 1.05 (95% CI: 0.99--1.11; *P* = 0.12).

![Forest plot for the overall association between the *GCK*−30G\>A polymorphism and type 2 diabetes risk.](pone.0055727.g001){#pone-0055727-g001}
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###### Meta-analysis of the *GCK* −30G\>A polymorphism on type 2 diabetes risk.

![](pone.0055727.t002){#pone-0055727-t002-2}

  Sub-group analysis      No. of data sets   No. of case/control       A allele        Dominant model   Recessive model                                                                                                 
  ---------------------- ------------------ --------------------- ------------------- ---------------- ----------------- ------- ------------------- -------- ---------- ------- ------------------- ------- ---------- ----------
  Overall                        36             88229/210239       1.06 (1.03--1.09)      \<10^−4^           0.003                1.08 (1.01--1.19)   0.003     0.009             1.12 (1.01--1.25)   0.008    0.001    
  Ethnicity                                                                                                               0.01                                            0.006                                           0.003
  Caucasian                      23             66376/173889       1.08 (1.04--1.12)      \<10^−4^           0.002                1.13 (1.04--1.21)   0.0007    0.0006            1.17 (1.06--1.29)   0.002   \<10^−4^  
  Asian                          9               18272/33749       1.01 (0.98--1.05)        0.53             0.77                 0.96 (0.84--1.10)    0.57      0.82             1.05 (0.93--1.18)   0.76      0.34    
  Others                         4                3581/2601        1.13 (1.04--1.24)       0.006             0.49                 1.06 (1.03--1.13)   0.008      0.63             1.12 (1.05--1.24)   0.03      0.52    
  Sample size                                                                                                             0.001                                           0.006                                          \<10^−4^
  Small                          15              4640/12804        1.14 (1.04--1.25)       0.006             0.09                 1.17 (1.06--1.28)   0.009      0.21             1.23 (1.05--1.43)   0.01      0.10    
  large                          21             83589/197435       1.04 (1.01--1.07)       0.004             0.03                 1.09 (1.02--1.23)   0.006      0.13             1.11 (1.07--1.35)   0.002     0.18    
  Diagnostic criterion                                                                                                    0.44                                            0.53                                             0.14
  WHO criterion                  19             72385/169960       1.06 (1.01--1.11)        0.02             0.12                 1.07 (1.02--1.19)    0.01      0.31             1.09 (1.05--1.17)   0.003     0.29    
  ADA criterion                  7               6247/23265        1.13 (0.99--1.28)        0.06           \<10^−4^               1.06 (0.97--1.16)    0.13    \<10^−4^           1.18 (0.94--1.47)   0.20    \<10^−5^  
  Other criterion                10              9597/17014        1.05 (0.99--1.11)        0.12             0.24                 1.07 (0.97--1.19)    0.16      0.35             1.02 (0.87--1.19)   0.76      0.09    

Cochran's chi-square Q statistic test used to assess the heterogeneity in subgroups.

Cochran's chi-square Q statistic test used to assess the heterogeneity between subgroups.

Significant heterogeneity was present among the included studies (*P*\<0.05). In meta-regression analysis, mean age of cases (*P* = 0.31) and controls (*P* = 0.24) and genotyping method (*P* = 0.96) did not significantly explain such heterogeneity. By contrast, ethnicity (*P* = 0.02) and the sample size in cases (*P* = 0.01) was significantly correlated with the magnitude of the genetic effect, explaining 11% and 16% of the heterogeneity, respectively. Since significant between-study heterogeneity still maintained in Caucasian subgroup, hence studies on Caucasian populations is the main source of heterogeneity.

Association of GCK −30G\>A Variant with Impaired Glucose Regulation {#s3c}
-------------------------------------------------------------------

To investigate how glucose metabolism was related to glucokinase, we analyzed individuals with impaired glucose regulation (impaired glucose tolerance and/or impaired fasting glucose). The data on genotypes of the −30G\>A polymorphism among impaired glucose regulation cases and controls were available in 5 (including 3177 cases and 8970 controls) studies. In the overall analysis, the −30G\>A polymorphism of *GCK* was significantly associated with elevated impaired glucose regulation risk with a per-allele OR of 1.23 \[95% CI: 1.14--1.32; *P*(Z) \<10^−5^; *P*(Q) = 0.73; [Fig. 2](#pone-0055727-g002){ref-type="fig"}\]. Significant associations were also found under dominant \[OR = 1.24; 95% CI: 1.13--1.35; *P*(Z) \<10^−5^; *P*(Q) = 0.56\] and recessive \[OR = 1.52; 95% CI: 1.20--1.91; *P*(Z) = 0.004; *P*(Q) = 0.77\] genetic model.

![Forest plot for the overall association between the *GCK*−30G\>A polymorphism and impaired glucose regulation risk.](pone.0055727.g002){#pone-0055727-g002}

Association of GCK −30G\>A Variant with Fasting Plasma Glucose Level {#s3d}
--------------------------------------------------------------------

The data on fasting plasma glucose (FPG) level among subjects stratified by genotype of −30G\>A polymorphism were available in 6 studies, including 31,616 subjects. Significant increases of fasting plasma glucose level were observed in A allele carriers compared with non-carriers. Using the random-effects model, compared with G/G genotype, the WMD for heterozygous were 0.07 \[95%: 0.05--0.08, *P(Z)* \<10^−5^, *P(Q)* \<10^−5^; [Figure 3](#pone-0055727-g003){ref-type="fig"}\] and homozygous 0.15 \[95%:0.05--0.24, *P(Z)* = 0.001, *P(Q)*\<10^−5^\], respectively.

![Meta-analysis of weighted mean differences (WMD) of fasting plasma glucose levels between GG and GA genotype of −30G\>A polymorphism.](pone.0055727.g003){#pone-0055727-g003}

Sensitivity Analyses and Publication Bias {#s3e}
-----------------------------------------

Sensitivity analysis indicated that no single study influenced the pooled OR qualitatively, suggesting that the results of this meta-analysis are stable (data not shown). The shape of the funnel plots was symmetrical ([Figure S2](#pone.0055727.s002){ref-type="supplementary-material"}). The statistical results still did not show publication bias in these studies (Begg test, P = 0.21; Egger test, *P* = 0.60).

Discussion {#s4}
==========

Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight into the in vivo relationship between candidate genes and diseases. This is the most comprehensive meta-analysis examining the *GCK* −30G\>A polymorphism and the relationship to T2D risk. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the present meta-analysis combined 24 studies for T2D including 88, 229 cases and 210, 239 controls. Our results demonstrated that a modest association existed between the −30G\>A variant of *GCK* and T2D risk.

In meta-analysis, heterogeneity evaluation was always conducted in statistical analysis. Thus, several subgroup meta-analyses were performed. In the stratified analysis by ethnicity, significant associations were found in Caucasians for the polymorphism in all genetic models; while no associations were detected among Asians. There are several possible reasons for such differences. First, the distribution of the A allele varies extensively between different races, with a prevalence of ∼23% among Asians and ∼17% among Caucasians. Therefore, additional studies are warranted to further validate ethnic difference in the effect of this polymorphism on T2D risk. In addition, different populations usually have different linkage disequilibrium patterns. A polymorphism may be in close linkage with another nearby causal variant in one ethnic population but not in another. *GCK* −30G\>A polymorphism may be in close linkage with different nearby causal variants in different populations. Moreover, clinical heterogeneity like age, sex ratio, dietary, years from onset and disease severity may also explain the discrepancy. Finally, such different results could also be explained by study design or sample size. As significant between-study heterogeneity was found among Caucasian subgroup, so the result must be interpreted with caution since the Caucasian population reports in the subgroup analysis include a mixture of populations from very distant countries.

The present study also provides evidence that the −30G\>A polymorphism of *GCK* influences susceptibility to phenotypes of impaired glucose regulation. In terms of genetic versus environmental influences on T2D susceptibility, this finding supports previous heritability studies, including a Danish twin study, generating considerably higher heritability estimates for the impaired glucose tolerance state compared with manifest T2D [@pone.0055727-Poulsen1].

We also observed a significant effect of the −30G\>A variant on FPG levels. This confirms a recent observation in a French study [@pone.0055727-Vaxillaire1]. Therefore, this variant may have a non-negligible impact on human health. Indeed, there is strong evidence that even small changes in FPG, well below the impaired fasting glucose threshold of 6.1 mmol/l, may be associated with risk of cardiovascular morbidity and mortality [@pone.0055727-Coutinho1], [@pone.0055727-Panzer1]. In this context, the *GCK* (−30A) allele was previously shown to be associated with type 2 diabetes and increased risk for coronary heart diseases in both diabetic and nondiabetic samples [@pone.0055727-Mrz1]. The exact mechanism by which the *GCK* −30A allele causes hyperglycemia is uncertain, but its effect seems constant throughout the lifespan, although insulin secretion is known to decrease with age in the general population. This is in accordance with the constant effect of the *GCK* −30A allele on fasting glucose reported in several groups of normoglycemic subjects whose median age varied from 8 to 72 years [@pone.0055727-Vaxillaire1].

A number of factors predict T2D; however, detailed pathogenesis mechanisms of T2D remain a matter of speculation. GCK is a key regulatory enzyme in the pancreatic β-cell, and it plays a crucial role in determining the threshold for glucose-stimulated insulin secretion. Heterozygous inactivating mutations in GCK cause maturity-onset diabetes of the young subtype 2, in which hyperglycemia is present from birth. The decreased expression of functional GCK seems to be the cause of the observed hyperglycemia among maturity-onset diabetes of the young subtype 2 patients. The mechanism by which the −30G\>A polymorphism causes hyperglycemia is uncertain. Previously studies suggested that the minor A allele or a genetic variant with which it is in linkage disequilibrium may alters the expression of *GCK* [@pone.0055727-Rose1].

In interpreting the results, some limitations of this meta-analysis should be addressed. Firstly, in the subgroup analyses, different ethnicities were pooled in the other ethnic group which may bring in some heterogeneity. As studies among the other ethnic group are currently limited, further studies including a wider spectrum of subjects should be carried to investigate the role of these variants in different populations. Secondly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if all individual raw data were available, which would allow for the adjustment by other co-variants including age, drinking status, obesity, cigarette consumption, and other lifestyle. Thirdly, only published studies were included in this meta-analysis. Therefore, publication bias may have occurred, even though the use of a statistical test did not show it.

Despite these limitations, this meta-analysis suggests that *GCK* −30G\>A polymorphism was significantly associated with increased risk of T2D, particularly in Caucasian population. In addition, *GCK* --30A allele is a true risk factor for the development of impaired glucose regulation, having a significant impact on FPG level.
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